Danielle M. Karyadi

Danielle M. Karyadi

Auto-generated profile, based on publicly available information

Danielle M. Karyadi

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health , Rockville, MD

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2021 in Science
Verified
Journal Article
Closed access
PDF file
LMLindsay M. Morton
Lindsay M. Morton
DKDanielle M. Karyadi
Danielle M. Karyadi
CSChip Stewart
Chip Stewart
TBTetiana Bogdanova
Tetiana Bogdanova
EDEric T. Dawson
Eric T. Dawson
SCStephen J. Chanock
Stephen J. Chanock
Genomics of radiation-induced damage: The potential adverse effects of exposures to radioactivity from nuclear accidents can include acute consequences such as radiation sickness, as well as long-term sequelae such as increased risk of cancer. There have been a few studies examining transgenerational risks of radiation exposure but the results have been inconclusive. Morton et al. analyzed papillary thyroid tumors, normal thyroid tissue, and blood from hundreds of survivors of the Chernobyl nuclear accident and compared them against those of unexposed patients. The findings offer insight into the process of radiation-induced carcinogenesis and characteristic patterns of DNA damage associated with environmental radiation exposure. In a separate study, Yeager et al. analyzed the genomes of 130 children and parents from families in which one or both parents had experienced gonadal radiation exposure related to the Chernobyl accident and the children were conceived between 1987 and 2002. Reassuringly, the authors did not find an increase in new germline mutations in this population. Science , this issue p. eabg2538 , p. 725

22 August 2025 in Science Advances
Verified
Journal Article
Open access
DKDanielle M. Karyadi
Danielle M. Karyadi
TBTetiana Bogdanova
Tetiana Bogdanova
CMCato M. Milder
Cato M. Milder
SHStephen W. Hartley
Stephen W. Hartley
OLOlivia W. Lee
Olivia W. Lee
LMLindsay M. Morton
Lindsay M. Morton
Papillary thyroid carcinoma (PTC) incidence increased after childhood exposure to radioactive fallout from the Chornobyl accident. We investigated PTC genomic profiles to distinguish radiation-induced versus sporadic oncogenic drivers by modeling dose and molecular characteristics by driver category: BRAF V600E ( n = 132), RAS mutation ( n = 31), fusions generated from two breakpoints and 0.08). Clonal clock mutational signatures, marking the age of tumor initiation, were associated with age at the accident for Fusion 2B<20bp -PTC ( P = 8.2 × 10 −4 ) but not other drivers ( P > 0.21). Together, these results support a causal role for ionizing radiation in Fusion 2B<20bp -PTC as a group but not other drivers.

4 September 2025 in Carcinogenesis
Verified
Journal Article
Closed access
MMMitchell J Machiela
Mitchell J Machiela
WWWendy S W Wong
Wendy S W Wong
ZMZhi-Ming MAI
Zhi-Ming MAI
DKDanielle M Karyadi
Danielle M Karyadi
VDVladimir Drozdovitch
Vladimir Drozdovitch
SCStephen J. Chanock
Stephen J. Chanock
Radiation exposure is a well-established risk factor for leukemia. Clonal hematopoiesis (CH), the expansion of mutated hematopoietic cells, is also associated with increased leukemia risk and its frequency is higher in cancer patients following radiotherapy and chemotherapy. We investigated whether low to moderate environmental ionizing radiation determined by state-of-the-art dosimetric analysis was associated with CH in the Chornobyl Family Study (CFS). Our study conducted targeted high-depth sequencing and array genotyping to identify and characterize clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) in 882 participants from 292 CFS families. Fathers had mean bone marrow radiation doses of 0.24 Gy (range: 0–3.86) and mothers had mean doses of 0.009 Gy (range: 2 × 10−5–0.63). The expected relationship between increasing age and CHIP was observed. No detectable effect of red bone marrow radiation dose was observed for CHIP risk (Fathers: Excess OR (EOR)/Gy = 0.41; 95% confidence interval (CI) = −0.57,1.39; P-value = .42; Mothers (categorical model due to limited dose range): odds ratio (OR)0.01–0.09 versus <0.001 Gy = 0.73; 95% CI = 0.39,1.38; P-value = .33) and the distribution and types of CHIP and mCAs detected in CFS participants did not differ from that seen in previously published studies of unexposed populations. No transgenerational effect of parental gonadal radiation exposure was detected in the children (Fathers: P-value = .08; Mothers: P-value = .67). Our findings suggest the type and levels of radiation exposure investigated in CFS families are unlikely to be strong contributors to CH risk, which could have important implications for public health concerns following environmental exposure to low to moderate ionizing radiation.

9 September 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
SZShahriar A Zamani
Shahriar A Zamani
DKDanielle M Karyadi
Danielle M Karyadi
SHStephen W Hartley
Stephen W Hartley
TGTodd M Gibson
Todd M Gibson
JSJoshua N Sampson
Joshua N Sampson
LMLindsay M. Morton
Lindsay M. Morton
Background: Among childhood cancer survivors, germline rare variants in autosomal dominant cancer susceptibility genes could increase the risk of subsequent neoplasms, but risks for rarer subsequent neoplasms and by age at onset are not well understood. Methods: We pooled the Childhood Cancer Survivor Study and St Jude Lifetime Cohort (median follow-up = 29.7 years [range = 7.1-55.6 years]) to identify rare deleterious germline variants across 150 literature-based cancer susceptibility genes using the ClinVar (National Library of Medicine) and SnpEff tools. Conditional logistic regression evaluated overall and subsequent neoplasm–specific risk, matching up to 100 subsequent neoplasm–free control individuals to participants by age, sex, childhood cancer type, radiation dose, chemotherapy, study, and follow-up time. Results: Among 11 840 survivors, 2165 (18.3%) developed 1 or more subsequent neoplasms. Overall subsequent neoplasm risk was modestly increased for variant carriers in any autosomal dominant cancer susceptibility gene (288/2165 [13.3%] cases; 9.9% of control individuals; odds ratio [OR] = 1.4, 95% CI = 1.3 to 1.6; P = 5.0 × 10−7). Carriers of variants in cancer-specific autosomal dominant cancer susceptibility genes had higher subsequent neoplasm risks, particularly for glioma (OR = 20.4, 95% CI = 7.4 to 56.1; P = 2.7 × 10−10), colorectal cancer (OR = 5.9, 95% CI = 1.4 to 25.7; P = 9.1 × 10−3), bone/soft-tissue sarcoma (OR = 5.3, 95% CI = 2.2 to 12.7; P = 1.5 × 10−3), meningioma (OR = 4.0, 95% CI = 1.4 to 1.0; P = 3.2 × 10−3), basal cell carcinoma (OR = 3.5, 95% CI = 1.2 to 10.0; P = .020), and breast cancer (OR = 2.6, 95% CI = 1.8 to 3.9; P = 2.8 × 10−6), who were also more likely to develop such subsequent neoplasms at younger ages. Notably, all meningioma, sarcoma, and glioma subsequent neoplasms among carriers occurred before ages 20, 25, and 35 years, respectively. Conclusions: Survivors with rare germline variants in cancer-specific autosomal dominant cancer susceptibility genes had increased subsequent neoplasm risk, especially at younger ages. These findings offer a potential basis for enhancing risk-stratified long-term surveillance for childhood cancer survivors.

21 March 2026 in JNCI Cancer Spectrum
Verified
Journal Article
Closed access
SZShahriar A Zamani
Shahriar A Zamani
DKDanielle M Karyadi
Danielle M Karyadi
SHStephen W Hartley
Stephen W Hartley
TGTodd M Gibson
Todd M Gibson
JSJoshua N Sampson
Joshua N Sampson
LMLindsay M. Morton
Lindsay M. Morton
Childhood cancer radiation therapy (RT) increases subsequent neoplasm risk. Radiation dose may modulate DNA damage responses, but the small sample sizes of prior human studies of homologous recombination repair hampered dose-specific investigations. We pooled data for 12 180 survivors (8339 from the Childhood Cancer Survivor Study and 3841 from the St Jude Lifetime Cohort) to estimate associations between deleterious homologous recombination repair variants and RT-related subsequent neoplasms (most commonly breast cancer, meningioma, thyroid cancer, and sarcoma) using conditional logistic regression with matched controls. In all, 1253 (10.3%) survivors were homologous recombination repair variant carriers, and 1301 (10.7%) developed at least 1 RT-related subsequent neoplasms. Variants increased the risk of out-of-field RT-related subsequent neoplasms (cases, 40/190 [21.1%]; control individuals, 9.7%; odds ratio [OR] = 2.5, 95% confidence interval [CI] = 1.7 to 3.6; P = 4.80 ×10−6), with consistent results across cohorts (Childhood Cancer Survivor Study, OR = 2.5, 95% CI = 1.6 to 3.7, P = 3.77 ×10−5; St Jude Lifetime Cohort, OR = 2.5, 95% CI = 1.0 to 6.4, P = 3.07 ×10−2). No association was observed for in-field or near-field subsequent neoplasms or individuals not undergoing RT. Findings emphasize homologous recombination repair variant-conferred susceptibility to RT-related subsequent neoplasms and dose-dependent DNA damage repair.

5 November 2026 in Cancer Research Communications
Verified
Journal Article
Open access
DKDanielle M. Karyadi
Danielle M. Karyadi
TBTetiana Bogdanova
Tetiana Bogdanova
SHStephen W. Hartley
Stephen W. Hartley
VDVladimir Drozdovitch
Vladimir Drozdovitch
SMSergii V Masiuk
Sergii V Masiuk
LMLindsay M. Morton
Lindsay M. Morton
Recent data indicate that radiation-induced papillary thyroid carcinomas (PTC) after the 1986 Chornobyl accident can be distinguished from sporadic PTC by examining patterns of DNA damage related to the generation of oncogenic drivers. PTC with fusion/structural variant (SV) drivers generated from two breakpoints with <20 basepairs (bp) breakpoint loss/gain (fusion2B<20bp) were consistent with radiation causation based on a series of analyses, including higher frequency with increasing radiation dose and an even distribution by sex. In contrast, fusion≥3B≥1000bp-, RAS-, and BRAFV600E-driven PTC exhibited no dose association and female predominance, as observed in sporadic PTC. We conducted DNA and RNA sequencing and reconstructed thyroid radiation dose for 229 PTCs to replicate and extend previous reports. Combined analyses with 331 published PTCs enabled investigation of dose and sex distributions for additional, less common fusion/SV driver categories. Among newly characterized PTCs, only fusion2B<20bp had statistically significantly lower female predominance and higher dose compared with BRAFV600E (67.1% vs. 82.4% female, P=0.034; median dose=186 vs. 52 mGy, P=6.410-5; 0% vs. 11.0% in unexposed), replicating the previous report (pooled Psex=7.910-4; pooled Pdose=3.010-10). Analyses of additional fusion/SV driver categories revealed similarly elevated doses for fusion≥3B<20bp (N=4, median=203 mGy, P=9.210-3). Doses were also significantly higher but to a lesser extent for fusion2B<1000bp (N=34, median=131 mGy, P=6.210-4) and fusion≥3B<1000bp (N=13, median=127 mGy, P=5.010-5). Our results suggest that the amount of loss/gain at the fusion/SV driver breakpoint appears to be a more informative feature than the number of DNA DSBs for distinguishing radiation-induced from sporadic tumor groups in this dose range.